Highlights Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.73 ^USD	-4.42%		-22.77%	-74.15%

Jun. 11	Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	CI
Jun. 07	Top Premarket Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	Jun. 11	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Top Premarket Decliners	Apr. 26	MT
Top Midday Gainers	Apr. 25	MT
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	Apr. 11	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment	Jan. 25	DJ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	Jan. 25	CI
Processa Plans to Expand NGC-Cap Program Into Breast Cancer; Shares Soar	Jan. 19	MT
Processa Pharma Shares Jump Premarket After Expansion of NGC-Cap Program	Jan. 19	DJ
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer	Jan. 19	CI
Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine	Dec. 19	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care	23-08-17	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative	23-05-18	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Processa Pharmaceuticals, Inc. Announces Prioritization on Development of Next Generation Chemotherapies	23-02-21	CI
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial	22-12-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Highlights

Filters